|
1
|
Laws ER: Management of (malignant)
intracranial gliomas. Practical Handbook of Neurosurgery. 549–558.
2009. View Article : Google Scholar
|
|
2
|
Scott JN, Rewcastle NB, Brasher PM, Fulton
D, MacKinnon JA, Hamilton M, Cairncross JG and Forsyth P: Which
glioblastoma multiforme patient will become a long-term survivor? A
population-based study. Ann Neurol. 46:183–188. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wilcox ME, Yang W, Senger D, Rewcastle NB,
Morris DG, Brasher PM, Shi ZQ, Johnston RN, Nishikawa S, Lee PW and
Forsyth PA: Reovirus as an oncolytic agent against experimental
human malignant gliomas. J Natl Cancer Inst. 93:903–912. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Csatary LK, Gosztonyi G, Szeberenyi J,
Fabian Z, Liszka V, Bodey B and Csatary CM: MTH-68/H oncolytic
viral treatment in human high-grade gliomas. J Neurooncol.
67:83–93. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Freeman AI, Gomori JM, Linetsky E,
Zakay-Rones Z, Panet A, Libson E, Irving CS, Galun E and Siegal T:
Phase I/II trial of intravenous OV001 oncolytic virus in resistant
glioblastoma multiforme (GBM). J Clin Oncol. 22:15152004.
View Article : Google Scholar
|
|
6
|
Stanford MM and McFadden G: Myxoma virus
and oncolytic virotherapy: A new biologic weapon in the war against
cancer. Expert Opin Biol Ther. 7:1415–1425. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kirn DH and Thorne SH: Targeted and armed
oncolytic poxviruses: A novel multi-mechanistic therapeutic class
for cancer. Nat Rev Cancer. 9:64–71. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lun X, Yang W, Alain T, Shi ZQ, Muzik H,
Barrett JW, McFadden G, Bell J, Hamilton MG, Senger DL and Forsyth
PA: Myxoma virus is a novel oncolytic virus with significant
antitumor activity against experimental human gliomas. Cancer Res.
65:9982–9990. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lun XQ, Zhou H, Alain T, Sun B, Wang L,
Barrett JW, Stanford MM, McFadden G, Bell J, Senger DL and Forsyth
PA: Targeting human medulloblastoma: Oncolytic virotherapy with
myxoma virus is enhanced by rapamycin. Cancer Res. 67:8818–8827.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Almansour NM, Pirogova E, Coloe PJ, Cosic
I and Istivan TS: A bioactive peptide analogue for myxoma virus
protein with a targeted cytotoxicity for human skin cancer in
vitro. J Biomed Sci. 19:652012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Coffey MC, Strong JE, Forsyth PA and Lee
PW: Reovirus therapy of tumors with activated ras pathway. Science.
282:1332–1334. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Norman KL, Hirasawa K, Yang AD, Shields MA
and Lee PW: Reovirus oncolysis: The Ras/RalGEF/p38 pathway dictates
host cell permissiveness to reovirus infection. Proc Natl Acad Sci
USA. 101:pp. 11099–11104. 2004; View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Werden SJ and McFadden G: Pharmacological
manipulation of the Akt signaling pathway regulates myxoma virus
replication and tropism in human cancer cells. J Virol.
84:3287–3302. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Correa RJ, Komar M, Tong JG, Sivapragasam
M, Rahman MM, McFadden G, Dimattia GE and Shepherd TG: Myxoma
virus-mediated oncolysis of ascites-derived human ovarian cancer
cells and spheroids is impacted by differential AKT activity.
Gynecol Oncol. 125:441–450. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Smallwood SE, Rahman MM, Smith DW and
McFadden G: Myxoma virus: Propagation, purification, quantification
and storage. Curr Protoc Microbiol Chapter. 14:Unit: 14A.
12010.
|
|
16
|
Johnston JB, Barrett JW, Chang W, Chung
CS, Zeng W, Masters J, Mann M, Wang F, Cao J and McFadden G: Role
of the serine-threonine kinase PAK-1 in myxoma virus replication. J
Virol. 77:5877–5888. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang G, Barrett JW, Stanford M, Werden SJ,
Johnston JB, Gao X, Sun M, Cheng JQ and McFadden G: Infection of
human cancer cells with myxoma virus requires Akt activation via
interaction with a viral ankyrin-repeat host range factor. Proc
Natl Acad Sci USA. 103:pp. 4640–4645. 2006; View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hentschel SJ and Lang FF: Current surgical
management of glioblastoma. Cancer J. 9:113–125. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Thorne SH and Kirn DH: Future directions
for the field of oncolytic virotherapy: A perspective on the use of
vaccinia virus. Expert Opin Biol Ther. 4:1307–1321. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shah AC, Benos D, Gillespie GY and Markert
JM: Oncolytic viruses: Clinical applications as vectors for the
treatment of malignant gliomas. J Neurooncol. 65:203–226. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Norman KL, Farassati F and Lee PW:
Oncolytic viruses and cancer therapy. Cytokine Growth Factor Rev.
12:271–282. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hu CW, Yin GF, Wang XR, Ren BW, Zhang WG,
Bai QL, Lv YM, Li WL and Zhao WQ: IL-24 induces apoptosis via
upregulation of RNA-activated protein kinase and enhances
temozolomide-induced apoptosis in glioma cells. Oncol Res.
22:159–165. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Górski J, Mizak B and Chrobocińska M:
Control of rabbit myxomatosis in poland. Rev Sci Tech. 13:869–879.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rivers TM and Ward SM: Infectious
myxomatosis of rabbits: Preparation of elementary bodies and
studies of serologically active materials associated with the
disease. J Exp Med. 66:1–14. 1937. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Barrett JW, Alston LR, Wang F, Stanford
MM, Gilbert PA, Gao X, Jimenez J, Villeneuve D, Forsyth P and
McFadden G: Identification of host range mutants of myxoma virus
with altered oncolytic potential in human glioma cells. J
Neurovirol. 13:549–560. 2007. View Article : Google Scholar : PubMed/NCBI
|
